Total Clarity Wealth Management Inc. Takes Position in Cencora, Inc. $COR

Total Clarity Wealth Management Inc. bought a new stake in Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 738 shares of the company’s stock, valued at approximately $221,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. MGO One Seven LLC boosted its stake in shares of Cencora by 30.6% in the 2nd quarter. MGO One Seven LLC now owns 3,298 shares of the company’s stock valued at $989,000 after purchasing an additional 772 shares in the last quarter. Genesee Capital Advisors LLC boosted its stake in shares of Cencora by 1.8% in the 2nd quarter. Genesee Capital Advisors LLC now owns 6,072 shares of the company’s stock valued at $1,821,000 after purchasing an additional 110 shares in the last quarter. CWM LLC boosted its stake in shares of Cencora by 15.4% in the 2nd quarter. CWM LLC now owns 11,792 shares of the company’s stock valued at $3,536,000 after purchasing an additional 1,575 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Cencora in the 2nd quarter valued at $112,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of Cencora by 25.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 33,506 shares of the company’s stock valued at $10,047,000 after purchasing an additional 6,790 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR stock opened at $317.86 on Wednesday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The stock has a market cap of $61.63 billion, a PE ratio of 32.70, a price-to-earnings-growth ratio of 1.48 and a beta of 0.63. The stock has a 50-day moving average of $297.97 and a 200-day moving average of $292.34. Cencora, Inc. has a one year low of $223.92 and a one year high of $319.87.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. The company had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.Cencora’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 22.63%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on COR shares. Wells Fargo & Company upped their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Evercore ISI set a $340.00 price target on shares of Cencora in a research report on Wednesday, October 8th. Weiss Ratings reiterated a “buy (b)” rating on shares of Cencora in a research report on Wednesday, October 8th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Finally, Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research report on Saturday. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $320.00.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the sale, the chief executive officer directly owned 39,274 shares in the company, valued at approximately $11,389,460. This trade represents a 11.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,993 shares of company stock valued at $16,292,923. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.